## Hematology

### RESEARCH AND TRAINING DETAILS

<table>
<thead>
<tr>
<th>Category</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty</td>
<td>12</td>
</tr>
<tr>
<td>Joint Appointment Faculty</td>
<td>2</td>
</tr>
<tr>
<td>Research Fellows</td>
<td>4</td>
</tr>
<tr>
<td>Support Personnel</td>
<td>46</td>
</tr>
<tr>
<td>Direct Annual Grant Support</td>
<td>$3,820,777</td>
</tr>
<tr>
<td>Direct Annual Industry Support</td>
<td>$300,362</td>
</tr>
<tr>
<td>Peer Reviewed Publications</td>
<td>36</td>
</tr>
</tbody>
</table>

### CLINICAL ACTIVITIES AND TRAINING

<table>
<thead>
<tr>
<th>Category</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Staff</td>
<td>6</td>
</tr>
<tr>
<td>Clinical Fellows</td>
<td>5</td>
</tr>
<tr>
<td>Other Students</td>
<td>3</td>
</tr>
<tr>
<td>Inpatient Encounters</td>
<td>1,765</td>
</tr>
<tr>
<td>Outpatient Encounters</td>
<td>5,465</td>
</tr>
</tbody>
</table>


3. Crosby LE, Quinn CT, Kalinyak KA. A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. *Advances in therapy*. 2015; 32:293-305.


---

**Faculty, Staff, and Trainees**

**Faculty Members**

**Russell Ware, MD, PhD**, Professor  
**Leadership** Director, Division of Hematology; Co-Executive Director, Cancer and Blood Diseases Institute  
**Research Interests** Sickle cell disease; hemolytic anemia; immune-mediated cytopenia; PNH.

**Ralph Gruppo, MD**, Professor  
**Leadership** Director, Comprehensive Hemophilia and Thrombosis Center  
**Research Interests** Coagulation; hemophilia; thrombosis.

**Karen Kalinyak, MD**, Professor  
**Leadership** Director of Outcomes and Quality Improvement  
**Research Interests** Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathies.

**Theodosia Kalfa, MD, PhD**, Associate Professor
**Research Interests** Study of erythropoiesis, red blood cell structural membrane biology, and of reactive oxygen species in sickle cell disease.

**Lori Luchtman-Jones, MD**, Professor  
**Leadership** Director of Thrombosis Research  
**Research Interests** Pediatric hematology: thrombosis; hemostasis; stroke.

**Patrick McGann, MD, MS**, Assistant Professor  
**Research Interests** Global hematology; hydroxyurea for sickle cell anemia.

**Eric Mullins, MD**, Assistant Professor  
**Leadership** Research Director, Hemophilia Treatment Center  
**Research Interests** Interactions between hemostatic factors and the immune system in inflammatory disease; hemophilia.

**Omar Niss, MD**, Instructor  
**Research Interests** Pediatric hematology; sickle cell disease; hemoglobinopathies; immune mediated cytopenias.

**Joseph Palumbo, MD**, Associate Professor  
**Leadership** Director, Comprehensive Thrombophilia Center  
**Research Interests** Dissecting the mechanisms coupling the hemostatic and innate immune systems to cancer progression.

**Charles Quinn, MD, MS**, Associate Professor  
**Leadership** Director, Erythrocyte Diagnostic Laboratory; Medical Director, Pediatric Sickle Cell Program  
**Research Interests** Sickle cell disease: causes and treatment of stroke in sickle cell disease; pathophysiologic role of hemoglobin desaturation; acute sickle cell pain; survival and long-term follow-up of children with sickle cell disease.

**Lisa Shook, MA, MCHES**, Instructor  
**Leadership** Administrative Director of the Comprehensive Sickle Cell Center  
**Research Interests** Sickle cell disease and trait; newborn screening; transition; chronic disease self-management; health education; quality improvement outcomes.

**Cristina Tarango, MD**, Assistant Professor  
**Leadership** Clinical Director, Hematology Division; Medical Director, Hemophilia Treatment Center  
**Research Interests** Thrombosis and hemostasis; medical education.

**Joint Appointment Faculty Members**

**Punam Malik, MD**, Professor (Experimental Hematology and Cancer Biology)  
**Ahna Pai, PhD**, Associate Professor (Behavioral Medicine and Clinical Psychology)

**Clinical Staff Members**

- **Viia Anderson, MSN, CNP-PC**
- **Susan Hoelle, RN, CNP**
- **Margaret Kaiser, MSN, CPNP**
- **Stephanie Lenahan, PA-C**
- **Darice Morgan, MSN, CPNP, FNP, BC**, APRN Program Lead for Hematology
- **Kathy Schibler, MSN, CPNP**
Trainees

- Nihal Bakeer, MD, PL-VI, Cincinnati Children's Hospital Medical Center
- Satheesh Chonat, MD, PL-VI, Michigan State University-Sparrow Hospital
- Melissa Mark, MD, PL-IV, Eastern Virginia Medical School
- Kiersten Ricci, MD, PL-V, Cincinnati Children's Hospital Medical Center
- Beverly Schaefer, MD, PL-V, Thomas Jefferson University

Grants, Contracts, and Industry Agreements

<table>
<thead>
<tr>
<th>Grant and Contract Awards</th>
<th>Annual Direct</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adams, G</td>
<td></td>
</tr>
<tr>
<td>Thrombin Promotes Prostate Cancer Progression</td>
<td></td>
</tr>
<tr>
<td>The Ohio State University Research Foundation</td>
<td></td>
</tr>
<tr>
<td>7/1/2013-6/30/2015</td>
<td>$41,634</td>
</tr>
<tr>
<td>Gruppo, R</td>
<td></td>
</tr>
<tr>
<td>Hemophilia and Thrombosis Center</td>
<td></td>
</tr>
<tr>
<td>Cascade Hemophilia Consortium (Hemophilia Foundation of Michigan)</td>
<td></td>
</tr>
<tr>
<td>6/1/2003-5/31/2016</td>
<td>$114,597</td>
</tr>
<tr>
<td>ATHN Data Quality Counts Award</td>
<td></td>
</tr>
<tr>
<td>American Thrombosis &amp; Hemostatis Network</td>
<td></td>
</tr>
<tr>
<td>7/1/2014-6/30/2016</td>
<td>$5,150</td>
</tr>
<tr>
<td>Zimmerman Program for the Molecular and Clinical Biology of VWD</td>
<td></td>
</tr>
<tr>
<td>National Institutes of Health (Medical College of Wisconsin)</td>
<td></td>
</tr>
<tr>
<td>P01 HL081588</td>
<td>2/1/2013-1/31/2017</td>
</tr>
<tr>
<td>Hemophilia Prevention Network</td>
<td></td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention (Hemophilia Foundation of Michigan)</td>
<td></td>
</tr>
<tr>
<td>10/1/1997-9/29/2015</td>
<td>$20,900</td>
</tr>
<tr>
<td>Hemophilia Comprehensive Care</td>
<td></td>
</tr>
<tr>
<td>Maternal &amp; Child Health Bureau (Hemophilia Foundation of Michigan)</td>
<td></td>
</tr>
<tr>
<td>10/1/1997-5/31/2015</td>
<td>$22,000</td>
</tr>
</tbody>
</table>
Kalfa, T

Rho GTPases in Terminal Erythroid Maturation
National Institutes of Health

R01 HL116352  9/26/2012-6/30/2016  $245,000

Cincinnati Center of Excellence in Hemoglobinopathies Research - Research Project 1
National Institutes of Health

U01 HL117709  8/15/2013-5/31/2018  $130,506

Cincinnati Center of Excellence in Hemoglobinopathies Research - Summer Students
National Institutes of Health

Calnyak, K

The Mid-South Clinical Data Research Network
Patient-Centered Outcome Research Institute (Vanderbilt University)

7/1/2014-6/30/2016  $7,143

Mullins, E

Mechanisms Linking Hemostatic Factors to Neuroinflammatory Disease
National Institutes of Health

K08 HL105672  8/22/2011-7/31/2016  $121,375

Quinn, C

A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia
National Institutes of Health (Dana Farber Cancer Institute)

P50 HL110790  7/15/2012-6/30/2017  $64,000

Cincinnati Center of Excellence in Hemoglobinopathies Research - Research Project 3
National Institutes of Health

U01 HL117709  8/15/2013-5/31/2018  $133,476

Cincinnati Center of Excellence in Hemoglobinopathies Research - Translational Research Skills Development
National Institutes of Health

U01 HL117709  8/15/2013-5/31/2018  $221,382

Shook, L
Sickle Cell Treatment Demonstration Program
Health Resources & Services Administration (University of Cincinnati)
9/1/2011-8/31/2014 $2,248

Sickle Treatment and Outcomes Research in the Midwest - Treatment Demonstration Project
Health Resources & Services Administration
9/1/2014-8/31/2017 $766,452

Cincinnati Sickle Cell Project
Ohio Department of Health
7/01/1998-6/30/2016 $123,469

Ware, R
Accurate and Inexpensive Point-of-Care Diagnosis of Sickle Cell Anemia
Doris Duke Charitable Foundation (Rice University)
9/1/2013-8/31/2016 $45,306

TCD with Transfusions Changing to Hydroxyurea
National Institutes of Health
R01 HL095647 8/1/2013-7/31/2015 $1,596,553

Endothelialized Microfluidics for Sickle Cell Disease Research & Drug Discovery
National Institutes of Health (Emory University)
R01 HL121264 1/1/2014-12/31/2018 $11,778

Baby Hug Follow-up Study II Core Laboratory
National Institutes of Health (Clinical Trials & Surveys Cort)
HHSN2682012000023C 7/01/2013-12/31/2016 $104,798

Current Year Direct $3,820,777

Industry Contracts

Gruppo, R
Baxter Healthcare Corporate $42,424
Alexion Pharmaceuticals, Inc $3,147
Bayer HealthCare Pharmaceuticals, Inc $9,888
Biogen Idec MA Inc. $7,585
<table>
<thead>
<tr>
<th>Name</th>
<th>Company</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>F. Novo Nordic</td>
<td>Pharmaceuticals</td>
<td>$22,220</td>
</tr>
<tr>
<td>Pfizer, Inc</td>
<td></td>
<td>$1,450</td>
</tr>
<tr>
<td>Kalfa, T</td>
<td>Baxter Healthcare Corporate</td>
<td>$314</td>
</tr>
<tr>
<td>Mullins, E</td>
<td>Grifols, Inc</td>
<td>$8,142</td>
</tr>
<tr>
<td></td>
<td>Baxter Healthcare Corporate</td>
<td>$75,934</td>
</tr>
<tr>
<td>Palumbo, J</td>
<td>Bayer HealthCare Pharmaceuticals, Inc</td>
<td>$6,700</td>
</tr>
<tr>
<td>Quinn, C</td>
<td>Amgen, Inc.</td>
<td>$9,586</td>
</tr>
<tr>
<td></td>
<td>Eli Lilly and Company</td>
<td>$11,432</td>
</tr>
<tr>
<td></td>
<td>Adventrx Pharmaceuticals, Inc</td>
<td>$1,540</td>
</tr>
<tr>
<td>Ware, R</td>
<td>Bristol-Myers Squibb</td>
<td>$100,000</td>
</tr>
</tbody>
</table>

**Current Year Direct Receipts**

$300,362

**Total**

$4,121,139